Health insurance reimbursement for hyperlipidemic treatment should be modified

Published: 2008-04-28 06:59:00

Updated: 2008-04-28 06:59:00

The pharmacoeconomic issues of individual antihyperlipidemic agents should be evaluated in terms of various factors, according to the Korean Society of Cardiology and the Korean Society of Lipidology and Atherosclerosis.

In a statement addressed to the Health Insurance Review Agency, the two s...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK